A Study of Linvo-VR vs DVRd in Transplant-Eligible Adult Participants With Newly Diagnosed Multiple Myeloma (NDMM)

NCT07428369 · clinicaltrials.gov ↗

PHASE2,PHASE3

Phase

NOT_YET_RECRUITING

Status

1570

Enrollment

INDUSTRY

Sponsor class

Conditions

Multiple Myeloma (MM)

Interventions

DRUG: Linvoseltamab
DRUG: Bortezomib
DRUG: Lenalidomide
DRUG: Daratumumab
DRUG: Dexamethasone

Sponsor

Regeneron Pharmaceuticals